{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/addisons-disease/background-information/associated-conditions/","result":{"pageContext":{"chapter":{"id":"17d23b10-c34e-5042-866b-bee0409de21e","slug":"associated-conditions","fullItemName":"Associated conditions","depth":2,"htmlHeader":"<!-- begin field 62ee5f4f-6cc2-4f9e-bc65-9d7301d68467 --><h2>What conditions are associated with Addison's disease?</h2><!-- end field 62ee5f4f-6cc2-4f9e-bc65-9d7301d68467 -->","summary":"","htmlStringContent":"<!-- begin item 658e2f30-0f18-430d-82e9-c23aa4c76e6b --><!-- begin field 84d363b3-b3a0-48c3-b3bc-4d11610bd3d6 --><ul><li><strong>Addison's disease may occur in isolation but is associated with other autoimmune conditions in 50–80% of cases:</strong><ul><li>Conditions associated with Addison’s disease include autoimmune thyroid disease, pernicious anaemia, vitiligo, and type 1 diabetes mellitus.</li></ul></li><li><strong>Of people with autoimmune Addison's disease, about two-thirds have an autoimmune polyendocrine syndrome:</strong><ul><li><strong>Autoimmune polyendocrine syndrome type 1 </strong>(up to 15% of people with Addison's disease).<ul><li>Usually autosomal recessive.</li><li>Typically presents in childhood.</li><li>Triad of Addison's disease, hypoparathyroidism, and chronic candidiasis.</li><li>May also be associated with type 1 diabetes mellitus, hypogonadism, premature ovarian insufficiency, pernicious anaemia, autoimmune thyroid disease, chronic active hepatitis, immunoglobulin A deficiency, chronic atopic dermatitis, keratoconjunctivitis, vitiligo, and alopecia.</li></ul></li><li><strong>Autoimmune polyendocrine syndrome type 2 </strong>(more common).<ul><li>Complex genetic trait with links to human leukocyte antigen (HLA) major histocompatibility complex.</li><li>Usually involves Addison's disease and autoimmune thyroid disease or type 1 diabetes mellitus.</li><li>May also include premature ovarian insufficiency, vitiligo, pernicious anaemia, coeliac disease, and hypoparathyroidism.</li></ul></li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/addisons-disease/references/\">Husebye, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/addisons-disease/references/\">Michels, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/addisons-disease/references/\">Bancos, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/addisons-disease/references/\">Bensing, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/addisons-disease/references/\">Bornstein, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/addisons-disease/references/\">Barthel, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/addisons-disease/references/\">Betterle, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/addisons-disease/references/\">Addison’s Disease Clinical Advisory Panel, 2020b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/addisons-disease/references/\">Bensing, 2020</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/addisons-disease/references/\">Chantzichristos, 2020</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/addisons-disease/references/\">Simpson, 2020</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/addisons-disease/references/\">Thomsen, 2020</a>]</p><!-- end field 84d363b3-b3a0-48c3-b3bc-4d11610bd3d6 --><!-- end item 658e2f30-0f18-430d-82e9-c23aa4c76e6b -->","topic":{"id":"85552d74-8915-56ec-961e-2cbd611bb10a","topicId":"b9b069a1-e345-435c-8996-0f9b9532b3b3","topicName":"Addison's disease","slug":"addisons-disease","lastRevised":"Last revised in December 2020","chapters":[{"id":"5bb9a13a-2651-51da-9586-419b958fc24f","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"d1ae168c-5219-526e-967a-65c44cfe1635","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"1e817e04-330a-5085-a1a4-705eedbc89f4","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"ddd590cd-acdd-5ec5-8adc-56c10d49145e","slug":"changes","fullItemName":"Changes"},{"id":"904ce186-aff5-51bf-a48a-7302aa46f685","slug":"update","fullItemName":"Update"}]},{"id":"6dbcee75-0365-5555-a1cd-832f4af24189","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"e1642c54-2720-5915-a5be-5fd600b124ca","slug":"goals","fullItemName":"Goals"},{"id":"7825ef20-439f-5a33-a1ae-2d755d692128","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"2e7aa18d-cc25-541c-ab7f-4b19f3d06de0","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"db1986d0-14c7-5a6c-969a-00655c4a668f","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"81632eb8-f3bc-567b-8133-c41a4d4a4fa2","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"81b3a0d1-c071-5892-a290-537f0200588d","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"5d7951b5-eadd-5c95-8e28-85b6b87c2f84","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"79a65204-8744-50b7-8bd3-20e68fa2deda","slug":"definition","fullItemName":"Definition"},{"id":"8ebee041-b08d-5992-8fa2-bb3c352139ce","slug":"causes","fullItemName":"Causes"},{"id":"61809560-acc8-50ce-a0d9-9cb61f4f9626","slug":"prevalence","fullItemName":"Prevalence"},{"id":"17d23b10-c34e-5042-866b-bee0409de21e","slug":"associated-conditions","fullItemName":"Associated conditions"},{"id":"09e08490-22fd-533a-b608-ce8f9f582c4b","slug":"prognosis","fullItemName":"Prognosis"},{"id":"3c6f99c1-f2df-5737-90e6-e76b6d46aca8","slug":"complications","fullItemName":"Complications"}]},{"id":"c7ea2e16-11fc-593d-93d1-3e5925230b95","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"8a3c3cb0-df69-59af-ad90-59ea47f3334b","slug":"suspecting-addisons-disease","fullItemName":"Suspecting Addison's disease"},{"id":"06bbc518-94d9-5d80-9034-38d9fc908d11","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"},{"id":"1f586755-4c6f-517b-bf1a-11bc2c316b17","slug":"investigations-suspected-adrenal-insufficiency","fullItemName":"Investigations - suspected adrenal insufficiency"},{"id":"1f8be7d7-2b02-57ef-b9eb-e0311516195c","slug":"confirming-the-diagnosis","fullItemName":"Confirming the diagnosis"}]},{"id":"4f82a73e-a473-59f7-a364-72430effad0e","fullItemName":"Management","slug":"management","subChapters":[{"id":"821e3bea-ed78-52fe-84d5-48a1178fb408","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"388a3da2-1859-52c3-a2cc-af8f499f9f2f","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"356babd6-ce13-538d-a8e9-d08f6fda5e57","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"a075c8c7-e63f-5c68-b273-5dcda49584e7","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"278a095e-2c76-50e4-ad8d-f3516b51a1e8","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"d79162d2-ea8d-55fd-836e-ea1ad829d735","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"47224ede-71c8-5986-90e0-aa7e07da9461","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"3e6e08a5-28f2-51f5-a9e0-4408814a4bed","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"d5b26a91-7f89-52f2-a6b2-b9373ef97515","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"5d7951b5-eadd-5c95-8e28-85b6b87c2f84","slug":"background-information","fullItemName":"Background information"},"subChapters":[]}}},"staticQueryHashes":["3666801979"]}